TABLE 1.

Reproducibility of the PLx-RVP assay with positive controlsa

TargetCallMFI (SD)CV (%)No. of reactions analyzed
IPCAbsentNA (NA)NA1
Present7,800 (1,260)1669
HRVAbsent169 (106)6361
Present7,550 (702)99
Influenza virus AAbsent168 (122)7361
Present6,400 (714)119
Influenza virus BAbsent191 (110)5861
Present2,740 (927)349
PIV1Absent168 (104)6263
Present5,890 (391)77
PIV2Absent181 (122)6761
Present4,670 (1,100)249
PIV3Absent175 (96.3)5561
Present10,500 (843)89
PIV4aAbsent166 (121)7361
Present4,560 (473)109
PIV4bAbsent161 (118)7370
PresentNA (NA)NA0
RSV AAbsent167 (126)7561
Present9,650 (954)109
RSV BAbsent185 (109)5962
Present2,830 (768)278
HMPVAbsent193 (106)5561
Present8,310 (1,160)149
Ad BAbsent156 (112)7253
Present4,630 (612)138
Ad CAbsent220 (153)7062
Present6,240 (819)138
Ad EAbsent206 (129)6361
Present8,620 (1,400)169
CoV OC43Absent189 (88.9)4761
Present13,300 (2,760)219
CoV NL63Absent184 (123)6762
Present3,230 (772)248
CoV 229EAbsent187 (104)5661
Present6,450 (1,850)299
  • a Results were obtained over the course of 4 months, and a total of 70 reactions were performed; each reaction mixture was spiked with 2 of the 17 targets (PIV4b not included).